Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Invivyd doses first participants in phase 3 COVID-19 study evaluating antibody-vaccine co-administration

Invivyd (NASDAQ:IVVD) has initiated dosing in its LIBERTY Phase 3 clinical trial, a randomized, double-blind study designed to evaluate the safety, tolerability, and immunology of its investigational monoclonal antibody candidate, VYD2311, alone and co-administered with an mRNA COVID-19 vaccine in healthy adults.

Leia mais: Invivyd doses first participants in phase 3 COVID-19 study evaluating antibody-vaccine co-administration
Grafa

Alterity Therapeutics wins FDA alignment for pivotal Phase 3 neurodegenerative trial

Alterity Therapeutics (NASDAQ:ATHE) has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), securing critical regulatory alignment on the design of its upcoming pivotal Phase 3 clinical program for lead candidate ATH434.

Leia mais: Alterity Therapeutics wins FDA alignment for pivotal Phase 3 neurodegenerative trial
Grafa
Retail

J.M. Smucker Q4 earnings surge 20% as firm outlines 2027 outlook

The J.M. Smucker Company (NYSE:SJM) reported a 20% increase in fourth-quarter adjusted earnings per share, driven by favorable pricing actions and portfolio management, while issuing a forward-looking forecast that projects a modest revenue contraction for the upcoming fiscal year.

Leia mais: J.M. Smucker Q4 earnings surge 20% as firm outlines 2027 outlook
Grafa
Retail

Designer Brands Q1 sales edge higher on brand portfolio growth, reaffirms guidance

Designer Brands (NYSE:DBI) reported a slight expansion in its first-quarter top-line revenue, driven by strong growth within its wholesale division that helped offset softening demand across its core brick-and-mortar storefront network.

Leia mais: Designer Brands Q1 sales edge higher on brand portfolio growth, reaffirms guidance